CVS Caremark Corp., the nation’s largest prescription drug provider, announced plans for its largest acquisition in five years, the buyout of Coram LLC for about $2.1 billion.
In a statement, CVS announced Wednesday plans to acquire th company currently owned by Apria Healthcare Group. The move will allow CVS to expand is operations in the antibiotic, nutrition and pain therapy business through intravenous therapy.
The deal is CVS’s largest since it acquire Longs Drug Stores for $2.8 billion in 2008 following a bidding war with CVS rival Walgreens.
According to reports, the deal also marks the third-largest drug-retail acquisition deal in the past five years.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Google and South Carolina Clash Over State Records Demand
May 8, 2024 by
CPI
Telefonica Germany Teams Up with Amazon Web Services to Migrate 5G Customers
May 8, 2024 by
CPI
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
EU to Scrutinize Telecom Italia’s Network Sale to KKR
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI